Workflow
PNT2003
icon
Search documents
Lantheus (LNTH) Earnings Call Presentation
2025-06-25 12:08
NASDAQ: LNTH Lantheus Investor Presentation Building on our Foundation to Power the Future of Radiopharmaceuticals May 2025 © 2025 Lantheus. All rights reserved. Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Ac ...
Lantheus (LNTH) 2025 Earnings Call Presentation
2025-06-17 12:48
NASDAQ: LNTH Lantheus Investor Presentation BUILDING ON OUR FOUNDATION TO POWER THE FUTURE OF RADIOPHARMACEUTICALS 2025 Truist Securities MedTech Conference June 17, 2025 © 2025 Lantheus. All rights reserved. Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor ...
Lantheus Holdings(LNTH) - 2025 Q1 - Earnings Call Transcript
2025-05-07 13:00
Lantheus (LNTH) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Speaker0 Good morning. Welcome to Lantheus First Quarter twenty twenty five Conference Call. All lines have been placed on mute. This call is being recorded and a replay will be available in the Investors section of the company's website approximately two hours after the completion of the call and will be archived for at least thirty days. I'll now turn the call over to Mark Kanarney, Vice President of Investor Relations. Mark? Speaker1 Thank yo ...
Lantheus Completes Acquisition of Evergreen Theragnostics
Newsfilter· 2025-04-01 13:00
BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has completed its previously announced acquisition of Evergreen Theragnostics, Inc. ("Evergreen"), a clinical-stage radiopharmaceutical company. The acquisition was first announced on January 28, 2025. Through the tra ...